Akcea Therapeutics Inc (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals Inc, has named Michael D Price as its new executive vice president and chief financial officer, it was reported on Monday.
In the new role, Price will manage financial operations at the company including managing financial strategies and activities related to clinical and regulatory functions, commercial sales, marketing, manufacturing and supply chain.
Price has over 25 years of experience in the pharmaceutical industry. Prior to joining Akcea, he served as EVP and CFO and was elected to the company's board of directors of Novelion Therapeutics. He has also served as VP and CFO at Noven Pharmaceuticals Inc from 2007 to 2016. From 1992 to 2006, he has worked at Bentley Pharmaceuticals Inc serving as VP, CFO, treasurer and secretary. He was also a member of Bentley's board of directors for nine years.
GenSight Biologics reports first patient treated in GS010 REVISE study
Biophytis secures Asian partnership and investment to advance Phase 3 sarcopenia programme
OncoHost receives BIG Innovation Award in Health category
MemorialCare hospitals recognised in 2026 Women's Choice Awards
Champions Oncology expands bioanalytical services with new technology and leadership
PhaseV receives three industry honours for AI in clinical development
Galapagos plans to wind down cell therapy business following strategic review
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Revelation Pharma acquires Acacia Apothecary & Wellness
Viatris receives fifth consecutive recognition on Forbes' annual list of World's Best Employers
INOVIO announces inducement grant to new employee
AbbVie's Allergan Aesthetics announces Natrelle supplier agreement with Vizient